Attached files

file filename
8-K - FORM 8-K - MONSANTO CO /NEW/form8k.htm


Monsanto Company
800 North Lindbergh Blvd
St. Louis, Missouri 63167
Release
Immediately
 
 
Contact
Media:      Sara Miller  (314-694-5824)
 
Analysts:  Bryan Hurley (314-694-8148)

MONSANTOS SEEDS AND TRAITS PERFORMANCE DRIVES STRONG SECOND QUARTER GROWTH, REINFORCES CONFIDENCE IN FULL-YEAR OUTLOOK

Second quarter ongoing and as-reported EPS of $3.15 underpinned by growth in Seeds and Genomics segment, including record quarter for sales and gross profit in global soybean business
Growth drivers in place despite industry headwinds; Confirms full year EPS and free cash flow guidance

ST. LOUIS, April 2, 2014 - Monsanto Company (NYSE: MON) announced today that solid growth from its core seeds and traits business, including expansion of its global corn and soybean businesses, drove the companys strong second quarter results. With the second quarter performance, executives noted progress on all full year financial targets, including seeds and genomics gross profit growth, margin expansion and ongoing EBITDA growth. The company confirmed its fiscal year 2014 guidance for earnings per share of $5.00 to $5.20 on an ongoing basis and $5.02 to $5.22 on an as-reported basis and free cash flow guidance for fiscal year 2014, even with an estimated full year EPS effect of $0.15 to $0.20 from agricultural industry headwinds.
 
 
Second Quarter
 
Six Months
($ in millions)
 
2014
 
2013
 
2014
 
2013
Net Sales by Segment
 
 
 
 
 
 
 
 
Corn seed and traits
 
$
3,414

 
$
3,280

 
$
4,468

 
$
4,419

Soybean seed and traits
 
820

 
677

 
1,087

 
908

Cotton seed and traits
 
49

 
60

 
186

 
245

Vegetable seeds
 
219

 
199

 
376

 
355

All other crops seeds and traits
 
146

 
130

 
207

 
174

TOTAL Seeds and Genomics
 
$
4,648

 
$
4,346

 
$
6,324

 
$
6,101

 
 
 
 
 
 
 
 
 
Agricultural productivity
 
$
1,184

 
$
1,126

 
$
2,651

 
$
2,310

TOTAL Agricultural Productivity
 
$
1,184

 
$
1,126

 
$
2,651

 
$
2,310

 
 
 
 
 
 
 
 
 
TOTAL Net Sales
 
$
5,832

 
$
5,472

 
$
8,975

 
$
8,411

 
 
 
 
 
 
 
 
 
Gross Profit
 
$
3,447

 
$
3,070

 
$
5,010

 
$
4,467

 
 
 
 
 
 
 
 
 
Operating Expenses
 
$
1,029

 
$
958

 
$
2,027

 
$
1,846

Interest Expense – Net
 
$
17

 
$
8

 
$
46

 
$
36

Other Expense – Net
 
$
61

 
$
22

 
$
81

 
$
39

Net Income Attributable to Monsanto Company
 
$
1,670

 
$
1,483

 
$
2,038

 
$
1,822

 
 
 
 
 
 
 
 
 
Diluted Earnings per Share (See note 1.)
 
$
3.15

 
$
2.74

 
$
3.83

 
$
3.37

Item Affecting Comparability – EPS Impact
 
 
 
 
 
 

 
 

Income from discontinued operations
 

 
(0.01
)
 
(0.02
)
 
(0.02
)
Diluted Earnings per Share from Ongoing Business (For the definition of ongoing EPS, see note 1.)
 
$
3.15

 
$
2.73

 
$
3.81

 
$
3.35

Effective Tax Rate
 
29
%
 
29
%
 
29
%
 
28
%






 
 
 
Second Quarter
 
Six Months
Comparison as a Percent of Net Sales:
 
2014
 
2013
 
2014
 
2013
 
Gross profit
 
59%
 
56%
 
56%
 
53%
 
Selling, general and administrative expenses
 
11%
 
11%
 
14%
 
14%
 
Research and development expenses
 
7%
 
7%
 
9%
 
8%
 
Income from continuing operations before income taxes
 
40%
 
38%
 
32%
 
30%
 
Net income attributable to Monsanto Company
 
29%
 
27%
 
23%
 
22%

Nearly 80 percent of our growth in the quarter came from our core seeds and traits business, providing an important proof point that our business is on track and positioned well to deliver the growth we anticipated for 2014 even against a backdrop of greater variability in the agricultural sector this year, said Hugh Grant, chairman and chief executive officer for Monsanto. The performance speaks to the value our technology has demonstrated on the farm and the overall strength of our global business. Our broader portfolio enables us to deliver growth today, while also building the platforms that will help us bring additional value to farmers around the world in the years to come.

Results of Operations

The company achieved strong second quarter and first half results that reflect the continued growth of its global business. Net sales for the quarter increased $360 million to $5.8 billion in the three-month comparison driven in part by solid growth in both its soybean and corn portfolios. For the first six months, net sales increased to approximately $9 billion. After delays in the early part of the quarter from winter weather on logistics in the Northern Hemisphere, shipments in the companys seed business improved in the latter part of the quarter, avoiding any significant timing impacts from weather in the quarter.

Operating expenses were up $71 million in the second quarter compared to the prior year due in part to additional costs as the company invests in its precision agriculture and biologicals platforms. In the three-month comparison, selling, general and administrative (SG&A) expenses increased to $625 million. Quarterly research and development (R&D) expenses were up $44 million over the prior year period.

The company's second quarter earnings per share (EPS) was $3.15 on an ongoing and as-reported basis, compared to an EPS of $2.73 on an ongoing and $2.74 on an as-reported basis in the same quarter last year. EPS for the first six months of fiscal year 2014 was $3.81 on an ongoing and $3.83 on an as-reported basis, compared to an EPS of $3.35 on an ongoing and $3.37 on an as-reported basis in the same quarter last year. (For a reconciliation of EPS to ongoing EPS see note 1).

Cash Flow

For the first half of fiscal year 2014, cash flow from operations was a source of approximately $1.8 billion, slightly lower than the same period last year. Net cash required by investing activities for the first half of fiscal year 2014 was approximately $1.6 billion, compared to $301 million for the same period of fiscal year 2013. Net cash required by financing activities for the first half of 2014 was $147 million, compared to net cash required of $422 million for the same period of fiscal year 2013.

Free cash flow was a source of $290 million for the first half of fiscal year 2014, compared to a source of approximately $1.6 billion for the first half of fiscal year 2013. Key investments for business growth made in the first half of fiscal year 2014 include The Climate Corporation acquisition and Novozymes BioAg Alliance. (For a reconciliation of free cash flow, see note 1).

Coming off a second-consecutive quarter of record amount of cash used for share repurchases, Monsanto spent an additional $203 million on share buybacks in the second quarter. The company has used more than $1.5 billion for share buybacks over the last 12 months.

Outlook

Monsanto confirmed its fiscal year 2014 ongoing earnings per share guidance of $5.00 to $5.20. Full-year 2014 EPS guidance on an as-reported basis is expected in the range of $5.02 to $5.22 per share. (For a reconciliation of EPS, see note 1).






The companys guidance incorporates the effects related to agricultural industry headwinds, including currency fluctuations and lower corn acres in some key markets. The company estimates a $0.15 to $0.20 full year EPS effect incorporated into its guidance, largely driven by the currency effects. Monsanto also continues to expect strong operational growth from its core business, reflected in mid-to-high teens growth in EBITDA.

Monsanto expects a strong second half of the fiscal year, punctuated by a strong conclusion in its fourth quarter as the company expects a significantly smaller loss than in recent years driven by a number of core factors.

The company also reaffirmed free cash flow in the range of $600 million to $800 million for fiscal year 2014. The free cash flow guidance is inclusive of the cash used for the companys fiscal year 2014 acquisition of The Climate Corporation and recent BioAg Alliance with Novozymes. The company expects net cash provided by operating activities to be $2.9 billion to $3.3 billion, and net cash required by investing activities to be approximately $2.3 billion to $2.5 billion for fiscal year 2014, including capital expenditures and acquisition-related costs. (For a reconciliation of free cash flow, see note 1).










Seeds and Genomics Segment Detail

($ in millions)
Net Sales
 
Gross Profit
 
Second Quarter
 
Six Months
 
Second Quarter
 
Six Months
Seeds and Genomics
2014
 
2013
 
2014
 
2013
 
2014
 
2013
 
2014
 
2013
Corn Seed and Traits
$
3,414

 
$
3,280

 
$
4,468

 
$
4,419

 
$
2,253

 
$
2,083

 
$
2,903

 
$
2,769

Soybean Seed and Traits
820

 
677

 
1,087

 
908

 
539

 
395

 
707

 
513

Cotton Seed and Traits
49

 
60

 
186

 
245

 
28

 
44

 
120

 
171

Vegetable Seeds
219

 
199

 
376

 
355

 
96

 
106

 
164

 
189

All Other Crops Seeds and Traits
146

 
130

 
207

 
174

 
77

 
71

 
104

 
82

TOTAL Seeds and Genomics
$
4,648

 
$
4,346

 
$
6,324

 
$
6,101

 
$
2,993

 
$
2,699

 
$
3,998

 
$
3,724


 
($ in millions)
Earnings Before Interest & Taxes (EBIT)
 
 
 
 
 
Second Quarter
 
Six Months
 
 
Seeds and Genomics
 
2014
 
2013
 
2014
 
2013
 
 
EBIT (For a reconciliation of EBIT, see note 1.)
 
$
2,055

 
$
1,840

 
$
2,159

 
$
2,060

 

The Seeds and Genomics segment consists of the company’s global seeds and related traits business.

Sales in the Seeds and Genomics segment for the second quarter were $4.6 billion, an increase of $302 million over the same period last year. Growth in Seeds and Genomics gross profit represented almost 80 percent of the companys overall gross profit increase in the quarter. For the first six months, sales for the segment are up $223 million over the same period last year. Monsanto's global corn and soy businesses have led the Seeds and Genomics segment performance.

Monsanto achieved a record quarter for soybean sales and gross profit on the strength of its growing global soybean platform. That record quarter drove overall margin expansion in the soybean segment, with margins in the quarter improving by more than seven points. Within soybeans, Monsanto confirmed it reached three million acres of Intacta RR2 PRO soybeans, providing a revolutionary new platform for Latin America soybean growers and making it the largest launch of a soybean trait in the company's history. The company has focused on making sure farmers have a good experience with the product in its initial launch year and with new harvest results in hand confirmed Intacta RR2 PRO soybeans are matching the better than four bushel per acre yield advantage against first-generation Roundup Ready® soybeans that were achieved in Ground Breakers® trials.

The current and emerging opportunities in the companys global corn portfolio complement the quarterly performance of the soybean platform. In the quarter, the corn business delivered solid growth over last years strong second quarter, including an increase in margins of more than two and a half points that reflect the continued upgrade of its global portfolio and benefits from the companys improved cost position.









Agricultural Productivity Segment Detail

 
 ($ in millions)
Net Sales 
 
Gross Profit
 
 
Second Quarter
 
Six Months
 
Second Quarter
 
Six Months
 
2014
 
2013
 
2014
 
2013
 
2014
 
2013
 
2014
 
2013
Agricultural Productivity
$
1,184

 
$
1,126

 
$
2,651

 
$
2,310

 
$
454

 
$
371

 
$
1,012

 
$
743

TOTAL Agricultural Productivity
$
1,184

 
$
1,126

 
$
2,651

 
$
2,310

 
$
454

 
$
371

 
$
1,012

 
$
743


 
($ in millions)
Earnings Before Interest & Taxes (EBIT)
 
 
 
 
 
Second Quarter
 
Six Months
 
 
Agricultural Productivity
 
2014
 
2013
 
2014
 
2013
 
 
EBIT (For a reconciliation of EBIT, see note 1.)
 
$
308

 
$
256

 
$
758

 
$
526

 
 
Unusual Item Affecting EBIT:
 
 
 
 
 
 
 
 
 
 
EBIT from Discontinued Operations
 
$
8

 
$
6

 
$
22

 
$
17

 

The Agricultural Productivity segment consists of the crop protection products and lawn-and-garden herbicide products.

Net sales for the Agricultural Productivity segment in the first half of fiscal 2014 increasing $341 million over the same period last year.





Webcast Information
In conjunction with this announcement, Monsanto will hold a conference call at 8:30 a.m. central time (9:30 a.m. eastern time) today.  The call will focus on these results and future expectations, product performance, and an update of projects within the companys R&D pipeline. The call may include a discussion of strategic initiatives and other matters related to the companys business.

Presentation slides and a simultaneous audio webcast of the conference call may be accessed by visiting the company's website at www.monsanto.com/investors or http://edge.media-server.com/m/p/9y2f29ss/lan/en. Visitors may need to download Windows Media Player prior to listening to the webcast. Following the live broadcast, a replay of the webcast will be available on the Monsanto website for three weeks. Monsanto publishes details on upcoming webcasts on this website in both the Presentation and Financial Reports section and the Calendar of Events section. Investors should look to this site as the source of information on future investor conference webcasts. The site includes a calendar of upcoming investor events, details on accessing scheduled webcasts and information from previous investor events.

About Monsanto Company
Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. Monsanto remains focused on enabling both small-holder and large-scale farmers to produce more from their land while conserving more of our world's natural resources such as water and energy. To learn more about our business and our commitments, please visit: www.monsanto.com. Follow our business on Twitter® at www.twitter.com/MonsantoCo, on the company blog, Beyond the Rows at www.monsantoblog.com, or subscribe to our News Release RSS Feed.

Cautionary Statements Regarding Forward-Looking Information:
 
Certain statements contained in this release are "forward-looking statements," such as statements concerning the company's anticipated financial results, current and future product performance, regulatory approvals, business and financial plans and other non-historical facts. These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: continued competition in seeds, traits and agricultural chemicals; the company's exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public acceptance of biotechnology products; the success of the company's research and development activities; the outcomes of major lawsuits and the previously-announced SEC investigation; developments related to foreign currencies and economies; successful operation of recent acquisitions; fluctuations in commodity prices; compliance with regulations affecting our manufacturing; the accuracy of the company's estimates related to distribution inventory levels; the company's ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters and accidents on the agriculture business or the company's facilities; and other risks and factors detailed in the company's most recent Form 10-K Report to the SEC. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this release. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results.
 
Notes to editors: Monsanto and the Vine Design, Intacta RR2 PRO and Ground Breakers are trademarks of Monsanto Company and its wholly-owned subsidiaries.

-oOo-






Monsanto Company
Selected Financial Information
(Dollars in millions, except per share amounts)
Unaudited

Statements of Consolidated Operations
Three Months Ended
 
Six Months Ended
 
Feb. 28, 2014
 
Feb. 28, 2013
 
Feb. 28, 2014
 
Feb. 28, 2013
Net Sales
$
5,832

 
$
5,472

 
$
8,975

 
$
8,411

Cost of Goods Sold
2,385

 
2,402

 
3,965

 
3,944

Gross Profit
3,447

 
3,070

 
5,010

 
4,467

Operating Expenses:
 
 
 
 
 

 
 

Selling, General and Administrative Expenses
625

 
598

 
1,214

 
1,140

Research and Development Expenses
404

 
360

 
813

 
706

Total Operating Expenses
1,029

 
958

 
2,027

 
1,846

Income From Operations
2,418

 
2,112

 
2,983

 
2,621

Interest Expense
40

 
35

 
93

 
86

Interest Income
(23
)
 
(27
)
 
(47
)
 
(50
)
Other Expense, Net
61

 
22

 
81

 
39

Income from Continuing Operations Before Income Taxes
2,340

 
2,082

 
2,856

 
2,546

Income Tax Provision
672

 
603

 
824

 
725

Income from Continuing Operations Including Portion Attributable to Noncontrolling Interest
$
1,668

 
$
1,479

 
$
2,032

 
$
1,821

Discontinued Operations:
 
 
 
 
 

 
 

Income from Operations of Discontinued Businesses
8

 
6

 
22

 
17

Income Tax Provision
4

 
2

 
9

 
6

Income from Discontinued Operations
4

 
4

 
13

 
11

Net Income
$
1,672

 
$
1,483

 
$
2,045

 
$
1,832

Less: Net Income Attributable to Noncontrolling Interest
2

 

 
7

 
10

Net Income Attributable to Monsanto Company
$
1,670

 
$
1,483

 
$
2,038

 
$
1,822

 
 
 
 
 
 
 
 
EBIT (see note 1)
$
2,363

 
$
2,096

 
$
2,917

 
$
2,586

 
 
 
 
 
 
 
 
Basic Earnings per Share Attributable to Monsanto Company:
 
 
 
 
 

 
 

Income from Continuing Operations
$
3.18

 
$
2.77

 
$
3.86

 
$
3.39

Income from Discontinued Operations

 
0.01

 
0.02

 
0.02

Net Income Attributable to Monsanto Company
$
3.18

 
$
2.78

 
$
3.88

 
$
3.41

 
 
 
 
 
 
 
 
Diluted Earnings per Share Attributable to Monsanto Company:
 
 
 
 
 

 
 

Income from Continuing Operations
$
3.15

 
$
2.73

 
$
3.81

 
$
3.35

Income from Discontinued Operations

 
0.01

 
0.02

 
0.02

Net Income Attributable to Monsanto Company
$
3.15

 
$
2.74

 
$
3.83

 
$
3.37

 
 
 
 
 
 
 
 
Weighted Average Shares Outstanding:
 
 
 
 
 

 
 

Basic
524.8

 
534.8

 
525.9

 
534.8

Diluted
530.3

 
540.9

 
531.6

 
540.9









Monsanto Company
Selected Financial Information
(Dollars in millions, except per share amounts)
Unaudited

Condensed Statements of Consolidated Financial Position
 
As of
 
As of
 
 
Feb. 28, 2014
 
Aug. 31, 2013
Assets
 
 
 
 
Current Assets:
 
 
 
 
Cash and cash equivalents (variable interest entity restricted - 2014: $15 and 2013: $140)
 
$
3,805

 
$
3,668

Short-term investments
 
45

 
254

Trade receivables, net (variable interest entity restricted - 2014: $129 and 2013: $0)
 
2,515

 
1,715

Miscellaneous receivables
 
668

 
748

Deferred tax assets
 
591

 
579

Inventory, net
 
3,692

 
2,947

Other current assets
 
234

 
166

Total Current Assets
 
11,550

 
10,077

Property, Plant and Equipment, Net
 
4,735

 
4,654

Goodwill
 
4,327

 
3,520

Other Intangible Assets, Net
 
1,645

 
1,226

Noncurrent Deferred Tax Assets
 
459

 
454

Long-Term Receivables, Net
 
131

 
237

Other Assets
 
610

 
496

Total Assets
 
$
23,457

 
$
20,664

Liabilities and Shareowners’ Equity
 
 

 
 

Current Liabilities:
 
 

 
 

Short-term debt, including current portion of long-term debt
 
104

 
51

Accounts payable
 
847

 
995

Income taxes payable
 
630

 
91

Accrued compensation and benefits
 
334

 
492

Accrued marketing programs
 
1,018

 
1,078

Deferred revenues
 
863

 
517

Grower production accruals
 
225

 
60

Dividends payable
 
226

 
228

Customer payable
 
31

 
12

Miscellaneous short-term accruals
 
773

 
812

Total Current Liabilities
 
5,051

 
4,336

Long-Term Debt
 
3,051

 
2,061

Postretirement Liabilities
 
333

 
357

Long-Term Deferred Revenue
 
94

 
138

Noncurrent Deferred Tax Liabilities
 
507

 
469

Long-Term Portion of Environmental and Litigation Reserves
 
187

 
193

Other Liabilities
 
393

 
382

Monsanto Shareowners’ Equity
 
13,678

 
12,559

Noncontrolling Interest
 
163

 
169

Total Shareowners’ Equity
 
13,841

 
12,728

Total Liabilities and Shareowners’ Equity
 
$
23,457

 
$
20,664

Debt to Capital Ratio:
 
19
%
 
14
%






Monsanto Company
Selected Financial Information
(Dollars in millions, except per share amounts)
Unaudited
Statements of Consolidated Cash Flows
 
Six Months Ended
 
 
Feb. 28, 2014
 
Feb. 28, 2013
Operating Activities:
 
 
 
 
Net Income
 
$
2,045

 
$
1,832

Adjustments to reconcile cash provided by operating activities:
 
 

 
 

Items that did not require (provide) cash:
 
 

 
 

Depreciation and amortization
 
332

 
305

Bad-debt expense
 
20

 
10

Stock-based compensation expense
 
57

 
49

Excess tax benefits from stock-based compensation
 
(36
)
 
(47
)
Deferred income taxes
 
32

 
52

Equity affiliate (income) expense, net
 
4

 
(2
)
Net gain on sales of a business or other assets
 
(2
)
 
(14
)
Other items
 
42

 
(37
)
Changes in assets and liabilities that provided (required) cash, net of acquisitions:
 
 
 
 
Trade receivables, net
 
(705
)
 
(201
)
Inventory, net
 
(742
)
 
(243
)
Deferred revenues
 
313

 
301

Accounts payable and other accrued liabilities
 
588

 
25

Pension contributions
 
(49
)
 
(24
)
Other items
 
(53
)
 
(149
)
Net Cash Provided by Operating Activities
 
1,846

 
1,857

Cash Flows (Required) Provided by Investing Activities:
 
 

 
 

Purchases of short-term investments
 
(105
)
 
(320
)
Maturities of short-term investments
 
314

 
312

Capital expenditures
 
(471
)
 
(261
)
Acquisitions of businesses, net of cash acquired
 
(922
)
 
(79
)
Purchases of long-term debt and equity securities
 
(12
)
 

Technology and other investments
 
(378
)
 
(48
)
Other proceeds
 
18

 
95

Net Cash Required by Investing Activities
 
(1,556
)
 
(301
)
Cash Flows Provided (Required) by Financing Activities:
 
 

 
 

Net change in financing with less than 90-day maturities
 
(44
)
 
142

Short-term debt proceeds
 
28

 
1

Short-term debt reductions
 

 
(29
)
Long-term debt proceeds
 
999

 
16

Long-term debt reductions
 
(3
)
 
(2
)
Payments on other financing
 
(39
)
 

Debt issuance costs
 
(8
)
 

Treasury stock purchases
 
(764
)
 
(327
)
Stock option exercises
 
128

 
136

Excess tax benefits from stock-based compensation
 
36

 
47

Tax withholding on restricted stock and restricted stock units
 
(8
)
 
(3
)
Dividend payments
 
(453
)
 
(402
)
Dividend payments to noncontrolling interests
 
(19
)
 
(1
)
Net Cash Required by Financing Activities
 
(147
)
 
(422
)
Effect of Exchange Rate Changes on Cash and Cash Equivalents
 
(6
)
 
26

Net Increase in Cash and Cash Equivalents
 
137

 
1,160

Cash and Cash Equivalents at Beginning of Period
 
3,668

 
3,283

Cash and Cash Equivalents at End of Period
 
$
3,805

 
$
4,443









Monsanto Company
Selected Financial Information
(Dollars in millions)
Unaudited

1.
EBIT, Ongoing EPS and Free Cash Flow:  The presentations of EBIT, ongoing EPS and free cash flow are not intended to replace net income (loss) attributable to Monsanto Company, cash flows, financial position or comprehensive income (loss), and they are not measures of financial performance as determined in accordance with generally accepted accounting principles (GAAP) in the United States.  The following tables reconcile EBIT, ongoing EPS and free cash flow to the respective most directly comparable financial measure calculated in accordance with GAAP.

Reconciliation of EBIT to Net Income (Loss):  EBIT is defined as earnings (loss) before interest and taxes.  Earnings (loss) is intended to mean net income (loss) attributable to Monsanto Company as presented in the Statements of Consolidated Operations under GAAP.  The following table reconciles EBIT to the most directly comparable financial measure, which is net income (loss) attributable to Monsanto Company.

 
 
 
Three Months Ended
 
Six Months Ended
 
 
Feb. 28, 2014
 
Feb. 28, 2013
 
Feb. 28, 2014
 
Feb. 28, 2013
EBIT – Seeds and Genomics Segment
 
$
2,055

 
$
1,840

 
$
2,159

 
$
2,060

EBIT – Agricultural Productivity Segment
 
308

 
256

 
758

 
526

EBIT– Total
 
2,363

 
2,096

 
2,917

 
2,586

Interest Expense, Net
 
17

 
8

 
46

 
36

Income Tax Provision(A)
 
676

 
605

 
833

 
728

Net Income Attributable to Monsanto Company
 
$
1,670

 
$
1,483

 
$
2,038

 
$
1,822

(A) Includes the income tax provision from continuing operations, the income tax benefit on noncontrolling interest, and the income tax provision on discontinued operations.
 
Reconciliation of EPS to Ongoing EPS:  Ongoing EPS is calculated excluding certain after-tax items which Monsanto does not consider part of ongoing operations.
 
 
Fiscal Year 2014
 
Three Months Ended
Six Months Ended
 
 
Guidance
 
Feb. 28, 2014
 
Feb. 28, 2013
 
Feb. 28, 2014
 
Feb. 28, 2013
Diluted Earnings per Share
 
$5.02-$5.22
 
$
3.15

 
$
2.74

 
$
3.83

 
$
3.37

Income from Discontinued Operations
 
(0.02)
 

 
(0.01
)
 
(0.02
)
 
(0.02
)
Diluted Earnings per Share from Ongoing Business
 
$5.00-$5.20
 
$
3.15

 
$
2.73

 
$
3.81

 
$
3.35







Reconciliation of Free Cash Flow:  Free cash flow represents the total of cash flows from operating activities and investing activities, as reflected in the Statements of Consolidated Cash Flows presented in this release.  With respect to the fiscal year 2014 free cash flow guidance, Monsanto does not include any estimates or projections of Net Cash Provided (Required) by Financing Activities because in order to prepare any such estimate or projection, Monsanto would need to rely on market factors and conditions that are outside of its control.
 
 
 
Fiscal Year 2014
 
Six Months Ended
 
 
 
Guidance
 
Feb. 28, 2014
 
Feb. 28, 2013
Net Cash Provided by Operating Activities
$
2,900-3,300
 
$
1,846

 
$
1,857

Net Cash Required by Investing Activities
 
(2,300)-(2,500)
 
(1,556
)
 
(301
)
Free Cash Flow
$
600-800
 
$
290

 
$
1,556

Net Cash Provided (Required) by Financing Activities
 
N/A
 
(147
)
 
(422
)
Effect of Exchange Rate Changes on Cash and Cash Equivalents
 
N/A
 
(6
)
 
26

Net Increase in Cash and Cash Equivalents
 
N/A
 
137

 
1,160

Cash and Cash Equivalents at Beginning of Period
 
N/A
 
3,668

 
3,283

Cash and Cash Equivalents at End of Period
 
N/A
 
$
3,805

 
$
4,443